• Product NameOCIAD2 Antibody
• Host SpeciesRabbit
• ClonalityPolyclonal
• PurificationAffinity chromatography purified via peptide column
• ApplicationsELISA WB IF
• Species ReactivityHu Ms Rt
• Immunogen TypePeptide
• Immunogen DescriptionRaised against a 17 amino acid peptide from near the amino terminus of human OCIAD2.
• Target NameOCIAD2
• Alternative Names    Ovarian cancer immuno-reactive antigen domain-containing protein 2, OCIA domain-containing protein 2
• Accession No. Swiss-Prot:Q56VL3
  Gene ID:132299
• UniprotQ56VL3
• Gene ID132299;
• Concentration 1mg/ml
• Formulation Supplied in PBS containing 0.02% sodium azide.
• Storage Can be stored at -20˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

OCIAD2 was identified by its sequence similarity with OCIAD1, and together OCIAD1 and OCIAD2 form the OCIA domain family. OCIAD2 mRNA was found to be expressed at higher levels in invasive adenocarcinoma mixed subtype with bronchioloalveolar carcinoma component (BAC) of the lung. Loss of OCIAD2 expression was significantly correlated with lymphatic invasion, blood vessel invasion, and lymph node metastasis, indicating that OCIAD2 may play a role in cell adhesion and prevention of cell migration. While the function of OCIAD2 is still unknown, its expression in adenocarcinoma with BAC component is significantly associated with a favorable prognosis and may serve as a marker for selecting tumors that are treatable by limited surgery.

• Western blot analysis of OCIAD2 in SK-N-SH cell lysate with OCIAD2 antibody at (A) 0.5 and (B) 1 ug/mL.
• Immunofluorescence of OCIAD2 in A549 cells with OCIAD2 antibody at 20 ug/mL.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting